RU2695133C1 - Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция - Google Patents

Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция Download PDF

Info

Publication number
RU2695133C1
RU2695133C1 RU2018117502A RU2018117502A RU2695133C1 RU 2695133 C1 RU2695133 C1 RU 2695133C1 RU 2018117502 A RU2018117502 A RU 2018117502A RU 2018117502 A RU2018117502 A RU 2018117502A RU 2695133 C1 RU2695133 C1 RU 2695133C1
Authority
RU
Russia
Prior art keywords
amine
pyrimidin
oxadiazol
cyclobutyl
difluoromethyl
Prior art date
Application number
RU2018117502A
Other languages
English (en)
Russian (ru)
Inventor
Юнтае Ким
Чанг Сик ЛИ
Дзунг Таек ОХ
Хиесеунг СОНГ
Дзин ЧОЙ
Дзаеиоунг ЛЕЕ
Original Assignee
Чонг Кун Данг Фармасьютикал Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чонг Кун Данг Фармасьютикал Корп. filed Critical Чонг Кун Данг Фармасьютикал Корп.
Application granted granted Critical
Publication of RU2695133C1 publication Critical patent/RU2695133C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2018117502A 2015-10-12 2016-10-11 Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция RU2695133C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0142014 2015-10-12
KR20150142014 2015-10-12
PCT/KR2016/011355 WO2017065473A1 (en) 2015-10-12 2016-10-11 Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
RU2695133C1 true RU2695133C1 (ru) 2019-07-22

Family

ID=58517488

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018117502A RU2695133C1 (ru) 2015-10-12 2016-10-11 Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция

Country Status (21)

Country Link
US (1) US10494355B2 (cg-RX-API-DMAC7.html)
EP (1) EP3362445B1 (cg-RX-API-DMAC7.html)
JP (1) JP6697074B2 (cg-RX-API-DMAC7.html)
KR (1) KR101839137B1 (cg-RX-API-DMAC7.html)
CN (1) CN108699048B (cg-RX-API-DMAC7.html)
AU (1) AU2016338118B2 (cg-RX-API-DMAC7.html)
CA (1) CA3001666C (cg-RX-API-DMAC7.html)
DK (1) DK3362445T3 (cg-RX-API-DMAC7.html)
ES (1) ES2940413T3 (cg-RX-API-DMAC7.html)
FI (1) FI3362445T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230201T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061967T2 (cg-RX-API-DMAC7.html)
MX (1) MX384527B (cg-RX-API-DMAC7.html)
MY (1) MY196174A (cg-RX-API-DMAC7.html)
NZ (1) NZ740809A (cg-RX-API-DMAC7.html)
PH (1) PH12018500773B1 (cg-RX-API-DMAC7.html)
PL (1) PL3362445T3 (cg-RX-API-DMAC7.html)
PT (1) PT3362445T (cg-RX-API-DMAC7.html)
RU (1) RU2695133C1 (cg-RX-API-DMAC7.html)
TW (1) TWI694073B (cg-RX-API-DMAC7.html)
WO (1) WO2017065473A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2831346C2 (ru) * 2021-04-08 2024-12-04 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазолтиокарбонильные соединения в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
SG11201706146UA (en) 2015-02-02 2017-08-30 Forma Therapeutics Inc 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2017018803A1 (en) 2015-07-27 2017-02-02 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
NZ736432A (en) 2015-07-27 2019-01-25 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2700696C2 (ru) 2015-07-27 2019-09-19 Чонг Кун Данг Фармасьютикал Корп. 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
HUE057544T2 (hu) 2015-08-04 2022-05-28 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények
RU2695133C1 (ru) 2015-10-12 2019-07-22 Чонг Кун Данг Фармасьютикал Корп. Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
KR102316234B1 (ko) * 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
AR117487A1 (es) * 2018-12-21 2021-08-11 Bayer Ag 1,3,4-oxadiazoles y derivados de éstos como agentes fungicidas
WO2020158762A1 (ja) * 2019-01-30 2020-08-06 武田薬品工業株式会社 複素環化合物
CN111848423B (zh) * 2019-04-30 2022-10-14 尚科生物医药（上海）有限公司 3-氧代环丁基氨基甲酸叔丁酯的制备方法
EP3976602A4 (en) 2019-05-31 2023-05-31 Chong Kun Dang Pharmaceutical Corp. 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
JP2022538284A (ja) 2019-06-27 2022-09-01 ザ ジョージ ワシントン ユニバーシティ， ア コングレッショナリー チャータード ノット－フォー－プロフィット コーポレイション Ｈｄａｃ６活性化マクロファージ、その組成物および使用
TWI882012B (zh) 2019-09-27 2025-05-01 日商武田藥品工業股份有限公司 雜環化合物
CA3165424A1 (en) * 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
US11339150B2 (en) 2019-12-27 2022-05-24 Onkure, Inc. Benzimidazole compounds as HDAC6 inhibitors
BR112022025692A2 (pt) 2020-06-19 2023-02-28 Bayer Ag 1,3,4-oxadiazóis e seus derivados como fungicidas
UY39276A (es) 2020-06-19 2022-01-31 Bayer Ag Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones.
WO2021255089A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft 1,3,4-oxadiazole pyrimidines and 1,3,4-oxadiazole pyridines as fungicides
UY39275A (es) 2020-06-19 2022-01-31 Bayer Ag 1,3,4-oxadiazol pirimidinas como fungicidas, procesos e intermediarios para su preparación, métodos de uso y usos de los mismos
UY39277A (es) 2020-06-19 2022-01-31 Bayer Ag Combinación de compuestos activos, método y uso de las mismas para controlar microorganismos dañinos y semilla tratada
JP2023537052A (ja) 2020-08-07 2023-08-30 イタルファルマコ ソシエタ ペル アチオニ 新規オキサジアゾール系の選択的ｈｄａｃ６阻害剤
WO2022197690A1 (en) * 2021-03-15 2022-09-22 The Regents Of The University Of Michigan Non-hydroxamate hdac6 inhibitors and related methods of use
KR20240013098A (ko) 2021-04-23 2024-01-30 테나야 테라퓨틱스, 인코포레이티드 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제
EP4333841A1 (en) 2021-05-04 2024-03-13 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
CA3217423A1 (en) 2021-06-16 2022-12-22 Jeffrey M. Schkeryantz Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
CN115572244B (zh) * 2021-06-21 2024-04-30 复旦大学 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途
EP4426285A4 (en) * 2021-11-04 2025-10-22 Valo Health Inc HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF
AU2023249346A1 (en) * 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Inhibiting histone deacetylase 6 (hdac6)
WO2024033293A1 (en) * 2022-08-08 2024-02-15 Italfarmaco S.P.A. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors
CN115286615A (zh) * 2022-09-01 2022-11-04 深圳市真味生物科技有限公司 一种消旋尼古丁的制备方法
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2011133888A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120027874A1 (en) * 2010-05-12 2012-02-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013080120A1 (en) * 2011-11-28 2013-06-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0276432A3 (de) 1986-12-12 1988-10-26 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
KR100265385B1 (ko) 1998-02-27 2000-11-01 윤여표 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003028729A2 (en) 2001-10-03 2003-04-10 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
AU2006270322A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US8088791B2 (en) 2006-03-23 2012-01-03 Biots Scientific Management Pty Ltd Antibacterial agents
WO2007143822A1 (en) 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
EP2099489B1 (en) 2006-12-11 2014-05-21 Genentech, Inc. Compositions and methods for treating a neoplasm
CA2690141A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
KR100903743B1 (ko) 2007-08-28 2009-06-19 전병태 소화기계 질환개선 및 예방용 식품 조성물
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
RU2010122324A (ru) 2007-11-02 2011-12-10 Момента Фармасьютикалз, Инк. (Us) Полисахаридные композиции, не обладающие антикоагулянтными свойствами
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
WO2010123933A1 (en) 2009-04-20 2010-10-28 Institute For Oneworld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
KR20130010895A (ko) 2010-02-25 2013-01-29 피라말 엔터프라이지즈 리미티드 옥사디아졸 화합물, 그의 제조방법 및 용도
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP3216798A3 (en) 2010-12-09 2017-10-25 Wockhardt Limited Ketolide compounds
KR101262870B1 (ko) 2011-01-28 2013-05-09 환인제약 주식회사 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
EA201490228A1 (ru) 2011-07-08 2014-08-29 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
JP6272773B2 (ja) 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
SMT201800421T1 (it) 2013-09-06 2018-09-13 Aurigene Discovery Tech Ltd Derivati di 1,3,4-ossadiazolo e 1,3,4-tiadiazolo come immunomodulatori
PT3080125T (pt) 2013-12-12 2018-12-14 Chong Kun Dang Pharmaceutical Corp Novos derivados de azaindole como inibidores seletivos da histona-desacetilase (hdac) e composições farmacêuticas que compreendem os mesmos
BR112017010402B1 (pt) 2014-11-24 2023-12-12 Medifron Dbt Inc Carboxamida substituída à base de tiazol e oxazol e derivados de ureia como ligantes de receptor vanilóide ii
CN106349451B (zh) 2015-07-14 2020-11-13 罗门哈斯公司 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法
RU2700696C2 (ru) 2015-07-27 2019-09-19 Чонг Кун Данг Фармасьютикал Корп. 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция
NZ736432A (en) 2015-07-27 2019-01-25 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017018803A1 (en) * 2015-07-27 2017-02-02 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HUE057544T2 (hu) * 2015-08-04 2022-05-28 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazol-származék vegyületek mint hiszton deacetiláz 6 inhibitorok, és ezeket tartalmazó gyógyszerkészítmények
RU2695133C1 (ru) 2015-10-12 2019-07-22 Чонг Кун Данг Фармасьютикал Корп. Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032445A1 (ja) * 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2011133888A1 (en) * 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120027874A1 (en) * 2010-05-12 2012-02-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013080120A1 (en) * 2011-11-28 2013-06-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EA201491060A1 (ru) * 2011-11-28 2014-09-30 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
CN104744446A (zh) * 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARISH RAJAK et al.: "2,5-Disubstituted -1,3,4-oxadiazole/thiadiazoles as surface recognition moiety: Design and synthesis of novel hydroxamic besaed histone deacetylase inhibitors", BIOORGANIC & MEDICINAL CHEMISRTY LETTERS, 2011, vol.21, p.5735-5738. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2831346C2 (ru) * 2021-04-08 2024-12-04 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазолтиокарбонильные соединения в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция

Also Published As

Publication number Publication date
EP3362445B1 (en) 2023-01-25
JP6697074B2 (ja) 2020-05-20
PH12018500773A1 (en) 2018-10-29
PH12018500773B1 (en) 2018-10-29
KR101839137B1 (ko) 2018-03-26
NZ740809A (en) 2019-04-26
CA3001666C (en) 2021-03-30
TWI694073B (zh) 2020-05-21
FI3362445T3 (fi) 2023-03-21
WO2017065473A1 (en) 2017-04-20
MY196174A (en) 2023-03-20
MX2018004447A (es) 2018-08-01
HUE061967T2 (hu) 2023-09-28
EP3362445A4 (en) 2019-05-22
PL3362445T3 (pl) 2023-08-07
CN108699048B (zh) 2021-12-28
PT3362445T (pt) 2023-03-20
US10494355B2 (en) 2019-12-03
US20180273495A1 (en) 2018-09-27
KR20170043091A (ko) 2017-04-20
TW201716397A (zh) 2017-05-16
HRP20230201T1 (hr) 2023-03-31
CA3001666A1 (en) 2017-04-20
CN108699048A (zh) 2018-10-23
DK3362445T3 (da) 2023-02-27
JP2018530571A (ja) 2018-10-18
AU2016338118A1 (en) 2018-04-12
EP3362445A1 (en) 2018-08-22
BR112018007289A2 (pt) 2018-10-23
AU2016338118B2 (en) 2019-03-14
MX384527B (es) 2025-03-14
ES2940413T3 (es) 2023-05-08

Similar Documents

Publication Publication Date Title
RU2695133C1 (ru) Производные оксадиазоламина в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
CA2994688C (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2695227C1 (ru) Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
WO2002030891A1 (en) Aliphatic nitrogenous five-membered ring compounds
TW201125858A (en) Cyclohexane derivatives and uses thereof
US11420950B2 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
RU2392269C2 (ru) Производные арилоксиалкилкарбаматов, их получение и их применение в терапии
JP2023516102A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
JP7642859B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールチオカルボニル化合物およびこれを含む薬剤学的組成物
CN110372638B (zh) 哌嗪类ampk激动剂及其医药用途
JP2023521836A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
RU2822624C1 (ru) Производные 1,3,4-оксадиазола в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
BR112018007289B1 (pt) Compostos de derivado de oxadiazol amina como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HK40077295B (zh) 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物
FR2930940A1 (fr) Derives de pyrrole, leur preparation et leur application en therapeutique
HK1212968A1 (zh) 氨基环丁烷衍生物、其制备方法及其用作药物的用途
HK1212968B (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
HK1240927A1 (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
JPWO1997033870A1 (ja) 新規なピリジン誘導体及びこれを有効成分とする医薬